1.Design and application of improved cardiopulmonary resuscitation ( CPR) balloon mask
Mengting ZHAO ; Zhenni WANG ; Lujie ZHOU ; Qianqian LIN ; Jingjing LIN ; Weiqiong JIN
Chinese Journal of Modern Nursing 2016;22(9):1316-1318
Objective To analyze current problems of widely-used balloon-mask ventilation, to explore progress in improved cardiopulmonary resuscitation ( CPR) balloon mask research and its advantages, so as to develop emergency rescue instruments applicable to common people. Methods Self-designed oxygen-feeding device in improved balloon mask was used on full-automated computer CPR simulation manikin for 250 times, and experimental data were analyzed. Results Qualified aspiration rate of new balloon-pressing device was 92. 4%, with 7. 6% unqualified. Conclusions Improved CPR balloon mask is with high operability, feasibility and scientificity. The plenum standards conform to requirements of current pre-hospital first aid.
2.Effect of USP9X on Akt phosphorylation and platelet function
Xuemei JIA ; Shujun SHAO ; Lujie ZHOU ; Danxin DU ; Huangying LU ; Cheng CHEN ; Rong XIA
Chinese Journal of Blood Transfusion 2024;37(4):377-384
【Objective】 To explore the expression of USP9X in platelets and its effect on platelet function. 【Methods】 The expression of USP9X in human and mouse was evaluated by PCR and Western blot. Platelets from young and old mice were separated and prepared, and the expression of USP9X was detected. USP9X inhibitos were used to assess the regulation of USP9X in platelet function, including aggregation, ATP release and spreading. Platelet lysates were collected in different time points to evaluate the change of phosphorylation of Akt in USP9X inhibitors treated platelets. 【Results】 Both human and mouse platelets expressed USP9X. Compared to the young mice, the old mice showed significantly enhanced expression of USP9X(P<0.05). To assess the effect of USP9X on platelet function, USP9X inhibitor was used to pre-incubate platelets for 30 min and platelet function were examined later. Results showed that USP9X inhibitor significantly decreased platelet activation including aggregation, ATP release and spreading(P<0.05). Compared to the control group, the inhibitor treated group showed a significant decrease in the spreading area after 45 minutes. The Western blot results showed a significant decrease in Akt phosphorylation levels of platelets in the USP9X inhibitor treated group. 【Conclusion】 Both human and mouse platelet express USP9X, and inhibition of USP9X decreased platelet function including aggregation, ATP release and spreading. USP9X can also influence the phosphorylation of Akt. The inhibitor of USP9X may become a potential therapeutic target for thrombosis intervention.